Filtern
Volltext vorhanden
- ja (45)
Gehört zur Bibliographie
- ja (45)
Erscheinungsjahr
- 2020 (45) (entfernen)
Dokumenttyp
Sprache
- Englisch (45) (entfernen)
Schlagworte
- multiple myeloma (9)
- relapse (4)
- B cells (3)
- refractory (3)
- 18F-FDG PET/CT (2)
- cancer (2)
- inflammation (2)
- management (2)
- mortality (2)
- 11C-Methionine PET/CT (1)
- 3D culture (1)
- 68Ga-Pentixafor PET/CT (1)
- AKT-signaling (1)
- ALiOS (1)
- ASE formula (1)
- Adaptive cell transfer (1)
- Aspergillus fumigatus (1)
- Aspergillus sp. (1)
- Autologous hematopoietic stem cell transplantation (1)
- B cell (1)
- CAR T cell (1)
- CAR T cells (1)
- CCL3 (1)
- CCL4 (1)
- CCL5 (1)
- CCS (1)
- CD38 (1)
- CMV reactivation (1)
- COX2 expression (1)
- Candida sp. (1)
- Coronavirus Disease 2019 (1)
- Donor lymphocytes (1)
- EGFR (1)
- HB-EGF (1)
- HGF (1)
- HNSCC (1)
- Hämostase (1)
- Infectious complications (1)
- JCV (1)
- KRAS (1)
- MAPKAPK2 (1)
- MEK/ERK-signaling (1)
- MOR202 (1)
- MYC (1)
- Megakaryozyt (1)
- Met (1)
- Myeloma (1)
- NAFLD (1)
- NASH (1)
- NGS (1)
- NLRP3 (1)
- NRF2 (1)
- PD-L1 (1)
- PML (1)
- POU6F2-AS2 (1)
- Pom‐PAD‐Dara (1)
- Prodigy (1)
- Radiochemotherapy (1)
- Rectal cancer (1)
- Rhizopus arrhizus (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Surgery (1)
- Systemic sclerosis (1)
- T cell (1)
- T cells (1)
- TLR agonists (1)
- TNFSF14 (1)
- TNFSF4 (1)
- TSLP (1)
- Tdp-43 (1)
- Teichholz formula (1)
- Time interval (1)
- VCE (1)
- Western diet (1)
- Zink (1)
- acute lymphoblastic leukaemia (1)
- acute respiratory distress syndrome (1)
- adalimumab (1)
- adverse events (1)
- amplicon sequencing (1)
- amyotrophic lateral sclerosis (1)
- anticoagulation (1)
- antithrombotic therapy (1)
- anxiety (1)
- atrial fibrillation (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- axonal transcriptome (1)
- binding (1)
- blinatumomab (1)
- bone (1)
- bone marrow angiogenesis (1)
- bridging (1)
- cancer vaccines (1)
- capture (1)
- carfilzomib (1)
- cfRNA (1)
- chimeric antigen receptor (1)
- clinical trial (1)
- colonoscopy (1)
- common variable immunodeficiency (1)
- complications (1)
- corticosteroids (1)
- cytokines (1)
- daratumumab (1)
- ddPCR (1)
- definition (1)
- dendritic cells (1)
- discharge definition (1)
- donor-cell leukemia (1)
- drug screening (1)
- early detection (1)
- echocardiography (1)
- endothelial cells (1)
- extramedullary disease (1)
- fluorescence (1)
- fungal aerosolization (1)
- fungal infection (1)
- fungal infections (1)
- galactomannan (1)
- gene (1)
- genetic susceptibility (1)
- growth differentiation factor 15 (1)
- head and neck cancer (1)
- helicase (1)
- hematologic malignancies (1)
- hematological malignancies (1)
- hemodialysis (1)
- immune response (1)
- immune therapy (1)
- immunity (1)
- immuno-oncology (1)
- immunotherapeutics (1)
- immunotherapy (1)
- incidence (1)
- inflammasome (1)
- inflammation-induced tissue demage (1)
- interacts (1)
- interleukin 1 (1)
- interleukin 18 (1)
- invasive aspergillosis (1)
- kinease (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- lenalidomide (1)
- lentiviral transduction (1)
- life-threatening side-effects (1)
- liquid biopsy (1)
- low molecular heparin (1)
- lymphocytes (1)
- mantle cell lymphoma (1)
- mechanosensing (1)
- mechanotransduction (1)
- melanoma malignancy (1)
- memory B cells (1)
- metabolic tumor volume (MTV) (1)
- methionine (1)
- molecular diagnosis (1)
- monocytes (1)
- multiplex PCR (1)
- muscle (1)
- music (1)
- myokines (1)
- nOAC (1)
- natural killer cell (1)
- newly diagnosed (1)
- nicotinamide (1)
- novel therapies (1)
- nuclear receptors (1)
- nucleotide excision repair (1)
- obinutuzumab (1)
- oral anticoagulants (1)
- organoids (1)
- osteokines adaptation (1)
- pancreatectomy (1)
- pathophysiology (1)
- pattern (1)
- personalised medicine (1)
- porcine large animal model (1)
- postoperative bleeding (1)
- pre-clinical models (1)
- primary immunodeficiencies (1)
- progression (1)
- prostaglandin E2 (1)
- pulmonary immune response (1)
- radiogenomics (1)
- recognition (1)
- relaxation (1)
- rheumatoid arhritis (1)
- safety (1)
- serum biomarkers (1)
- small bowel bleeding (1)
- smoldering myeloma (1)
- stem cell transplantation (1)
- stress level (1)
- subunit (1)
- sulfur (1)
- superior (1)
- surgical care (1)
- t-lymphocytes (1)
- thromboembolism (1)
- tocilizumab (IL-6 inhibitor) (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- toxicity (1)
- transactivation (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tumor-specific CD8+ T cells (1)
- tumor‐specific antigen (1)
- venetoclax (1)
- video capsule endoscopy (1)
- warfarin interruption (1)
Institut
- Medizinische Klinik und Poliklinik II (45) (entfernen)
Sonstige beteiligte Institutionen
EU-Projektnummer / Contract (GA) number
- 733297 (2)
- 19-COP-0031 (1)
- 641458 (1)
- 754658 (1)
- 847507 (1)
- 853988 (1)
- EU-1650-0006 (1)
In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatment of relapsed/refractory (RR) MM, and early phase clinical trials have shown promising efficacy of CAR T cell therapy. Many patients with end stage RRMM regard CAR T cell therapy as their “last chance” and a “hope of cure”. However, severe adverse events (AEs) and even toxic death related to CAR T cell therapy have been observed. The management of AEs related to CAR T cell therapy represents a new challenge, as the pathophysiology is not fully understood and there is still no well-established standard of management. With regard to CAR T cell associated toxicities in MM, in this review, we will provide an overview of experience from clinical trials, pathophysiology, and management strategies.